Cambium Bio
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Unit 2, 31 Lexington Dr U 6, Bella Vista...Phone Number
+611300995098Website
cambium.bioRevenue
<$5 MillionStock Symbol
CMBIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Cambium Bio
Cambium Bio Limited (ASX: CMB) is a clinical-stage regenerative medicine company focused on developing novel biologic therapeutics for ophthalmology and tissue regeneration. Its proprietary technology harnesses human platelet lysate (HPL) and stem cell/secretome platforms to advance pipeline candidates including Elate Ocular® for dry eye disease, Progenza™ for knee osteoarthritis, and Sygenus™ for tissue repair.Explore more
Cambium Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cambium Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cambium Bio
Cambium Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Cambium Bio is spiking on competitors!
Check if Cambium Bio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Cambium Bio recently announced quarterly report
Product Launch: Get notified when Cambium Bio launches new products
Click to see if Cambium Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cambium Bio has new funding data
Recommended Actions
Find VP level buyers at Cambium Bio
Find 3 more new buyers
Cambium Bio financials insights
Gather financial insights about Cambium Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Private Equity
$1.9M
2026
Stock/Share Issuance
$5M
Debt
$2.7M
Cambium Bio Tech Stack
A closer look at the technologies used by Cambium Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Partnership, Pharmaceuticals, Healthcare Technology, Manufacturing Operations
Funding
Funding
Funding
Cambium Bio News & Media
Veterinary Vaccines Market 2025 Is Booming Worldwide by 2032 | Aratana Therapeutics Inc, Regeneus Ltd, Morphogenesis Inc
The Veterinary Vaccines Market is estimated to be valued at USD 10.46 Bn in 2025 and is expected to reach USD 17.70 Bn by 2032. BURLINGAME, CA, UNITED STATES, November 24, 2025 /EINPresswire.com/ -- The Veterinary Vaccines Market is estimated to be …Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio
TAIPEI, Sept. 29, 2025 /PRNewswire/ -- Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium Bio (ASX: CMB). Under the agreement, Cambium will entrust Locus Cell with the contract...Cambium Bio Secures A$2.12 Million in Fully-Subscribed Placement - Sharecafe
Cambium Bio Limited (ASX:CMB), a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair, has announced it has successfully raised A$2,119,418 through a placement of 4,570,667 new fully-paid ordinary shares. The placement utilised the company’s existing 15% placement capacity under ASX Listing Rule 7.1 and additional 10% capacity under Listing Rule 7.1A. The sharesCambium Bio Successfully Closes A$3.0M Financing Round
Cambium Bio Successfully Closes A$3.0M Financing Round
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cambium Bio
Sign Up For FreeTo access detailed company insights
Cambium Bio Limited (ASX: CMB) is a clinical-stage regenerative medicine company focused on developing novel biologic therapeutics for ophthalmology and tissue regeneration. Its proprietary technology harnesses human platelet lysate (HPL) and stem cell/secretome platforms to advance pipeline candidates including Elate Ocular® for dry eye disease, P... Read More
